Hypothesis generative head-to-head study comparing efficacy of afatinib and osimertinib based on immunological biomarkers in Japanese NSCLC patients with EGFR mutations (Heat on Beat study)

BACKGROUND: In the FLAURA trial, superiority of osimertinib over the standard of care (SOC) was not demonstrated in Asian patients; SOC seemed favorable among Japanese patients (hazard ratio 1.39, 95% confidence interval 0.82–2.33). Three reasons are suggested: since rechallenge with epidermal growt...

Descripción completa

Detalles Bibliográficos
Autores principales: Morikawa, Kei, Tanaka, Hisashi, Itani, Hidetoshi, Takata, Saori, Watanabe, Satoshi, Kishi, Kazuma, Soejima, Kenzo, Kaira, Kyoichi, Kagamu, Hiroshi, Yoshimura, Kenichi, Matsutani, Noriyuki, Seki, Nobuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Advances in Treatment of Lung Cancer Patients with Targetable Mutations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607717/
https://www.ncbi.nlm.nih.gov/pubmed/33193830
http://dx.doi.org/10.1177/1758835920967254

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607717/
https://www.ncbi.nlm.nih.gov/pubmed/33193830
http://dx.doi.org/10.1177/1758835920967254

Ejemplares similares